Xbrane Biopharma

Declaration of Voting Results & Voting Rights Announcements • May 31, 2023

Change of number of shares and votes in Xbrane

Xbrane Biopharma AB ("Xbrane" or the "Company") has according to previously announced information resolved to carry out a directed share issue of in total 1,709,986 shares. The share issue has resulted in a change of the registered share capital and shares and votes in Xbrane.

As of 31 may 2023, the total number of shares and votes in the Company amounts to 29,216,004. The Company's registered share capital amounts to approximately SEK 6,549,821.

Contacts

Martin Åmark, CEO M: +46 76 309 37 77 E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR M: +46 76 325 60 90 E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-05-31 08:00 CEST.

Attachments

Change of number of shares and votes in Xbrane